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Lipid emulsions were introduced into clinical practice more than five decades ago as a calorically dense, non-glucose-based 
energy source for parenteral nutrition. Recently, intravenous lipid emulsions have been used as rescue for systemic local 
anaesthetic toxicity. However, the non-nutritive, therapeutic roles of lipid emulsions have recently expanded. This review 
considers these newer uses of lipid emulsions as drug administration vehicles, for treatment of lipophilic drug toxicity, and as 
modifiers of ischaemia-reperfusion injury in the anaesthetic and critical care environments. The potential adverse effects of lipid 
emulsion administration are also succinctly addressed.
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Introduction
Lipid emulsions were introduced into clinical practice more than 
five decades ago as a calorically dense, non-glucose-based 
energy source for parenteral nutrition. Recently, these emulsions 
have been employed as ‘lipid rescue’ for systemic local anaesthetic 
toxicity.1 However, the non-nutritive therapeutic roles of lipid 
emulsions have recently expanded. These include their use as 
drug carrier vehicles, for management of lipophilic drug toxicity 
and as an exciting new adjuvant for the management of 
myocardial ischaemia-reperfusion injury (see Table 1).
Arvid Wretlind of the Karolinska Institute, Sweden devoted years 
solving the toxicity associated with previous intravenous fat 
solutions.2 This culminated with the 1962 introduction of 
Intralipid® (Fresenius Kabi, Bad Homburg, Germany), an emulsion 
comprising soybean oil, egg phospholipid, and glycerin (Table 2). 
Intralipid® is currently manufactured with lipid concentrations of 
10, 20 and 30%, these being commonly used as a drug carrier 
vehicle, ‘lipid rescue’, and the formulation of parenteral nutrition, 
respectively.3
Understanding emulsions
An emulsion is defined as any mixture of liquids that do not 
normally mix.4 An emulsion is formed by small liquid droplets 
being dispersed in a second liquid.5 The small droplets and the 
liquid into which they are dispersed are referred to as the 
incontinuous and continuous phases respectively. Therapeutic 
lipid emulsions are typically lipid droplets suspended in water; 
therefore the incontinuous and continuous phases are usually 
lipid and aqueous phases respectively (Figure 1).5 Inspection of 
an oil-and-vinegar salad dressing after it has stood for a while 
emphasises the inherent tendency of lipids to coalesce. To 
stabilise mixtures and prevent this from happening, emulsifiers 
are added to emulsions.7 Emulsifiers are both fat and water 
soluble, and a single molecular layer of the emulsifier arranges 
itself around the lipid droplet, surrounding it (Figure 1).7 
Phospholipids such as egg lecithin are commonly used as 
emulsifiers. For example, when egg is added to stabilise the oil-
and-vinegar mixture, the emulsion is known as mayonnaise.
Therapeutic lipid emulsions may be described as oil-in-water 
macroemulsions, with a droplet diameter between 0.1 and 100 
microns.6 The droplets are of similar shape and size to 
physiological chylomicrons, and are metabolised in a similar 
manner. These lipid droplets are large enough to reflect white 
light, which gives them their typical solid, milky appearance.6 
Indeed, the word ‘emulsion’ originates from the Latin ‘mulgere’ 
meaning ‘to milk out’.
The fatty acids (lipid phase) of lipid emulsions may originate from 
soya beans, safflower, coconut, olive, or fish oils.5,8 The origin of the 
fatty acids is important as it determines the ratio of medium- to 
long-chain triglycerides. This ratio imparts the emulsion with 
particular physiological qualities and also its side effect profile. 
Long-chain triglycerides are a rich source of essential omega-6 and 
omega-3 polyunsaturated fatty acids. Unfortunately, long-chain 
triglycerides are pro-inflammatory. They accelerate lipid 
peroxidation with deleterious effects on neutrophil function while 
their increased rate of arachidonic acid production aggravates pro-
inflammatory cytokine production.8 Medium-chain triglycerides 
are more stable and incur fewer immune modulatory and 
Table 1: Therapeutic roles of lipid emulsions
1. Parenteral nutrition
2. Drug carrier vehicle
3. Resuscitation from lipophilic drug toxicity
4. Reperfusion injury attenuation
Table 2: Intralipid® constituents
1. 20% Soybean oil
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inflammatory side effects. However, they undergo faster 
metabolism and incur the costs of increased energy expenditure, 
body temperature, and ketosis formation.8 Therefore, medium- 
and long-chain triglycerides are always combined, in an attempt to 
conserve caloric value, while minimising the side effects. 8
Various lipid emulsion preparations currently available for clinical 
use, with their associated fatty acid composition and corresponding 
emulsifier, are set out in Table 3.5,7,9 The interested reader is referred 
to detailed reviews of the physicochemical properties and fatty 
acid composition of lipid emulsions by Waitzberg and colleagues,5 
and Hippalgaonkar and colleagues.8
Lipid emulsion as a drug carrier
Lipid emulsions are useful carrier vehicles for lipophilic drugs.8 Lipid 
emulsions are used to deliver drugs to or via the skin (transdermal 
administration), to the eye, as well as parenterally. Propofol, etomidate, 
diazepam, amphotericin B, alprostadil (PEG1), dexamethasone, and 
certain vitamins (A, D2, E, K1) are examples of intravenous drugs 
formulated as emulsions.10 Intravenous formulations that use lipid 
emulsions as carrier vehicles have distinct advantages and 
disadvantages (Table 4). Two serious, underappreciated potential 
problems are emulsion instability and microbial contamination.
Emulsion instability
To exert an effect following intravenous administration, the lipid 
soluble drug must diffuse across the phospholipid emulsifier 
into the blood.6 The rate at which the drug will diffuse out of the 
lipid droplet is governed by the principles encompassed by Fick’s 
lawi, namely the concentration gradient across the lipid droplet 
membrane, the respective partition coefficients of the drug 
within the fat and aqueous states, and the surface area of the 
drug-containing lipid droplet. The single molecular layer 
emulsifier surrounding the lipid droplet slows the rate at which 
the free drug becomes available when compared with drugs 
formulated as aqueous solutions.
Oil-in-water macroemulsions are inherently unstable. Flocculation, 
coalescence and creaming (see Table 5) are a result of attraction 
between the lipid droplets and occur naturally in any lipid 
emulsion.6,11 Should lipid droplet size increase due to coalescence, 
the concomitant decreased surface area will further slow the rate of 
diffusion of drug into the blood with altered drug pharmacokinetics.6,11 
This stresses the importance of emulsion stability.
Flocculation and creaming can be reversed to some extent by 
gently shaking the ampoules before use.6,11 However, irreversible 
emulsion instability (severe coalescence) can be a consequence 
of extreme agitation, temperature variation and alteration of the 
aqueous phase. Adding charged substances to the formulation 
(e.g. dilution with lignocaine, water, or normal saline) causes 
disruption of the negatively charged, mutually repelling droplet 
surfaces. This incites adhesion and coalescence with a tenfold or 
greater increase in droplet size, which may result in pulmonary, 
splenic, placental, and cerebral microembolisation.12,13 Only high 
shear homogenisation with re-filtration will ensure reversal of 
emulsion degradation of this severity. Mixing or diluting 
propofol, or for that matter any drug formulated as a lipid 
emulsion, is therefore strongly discouraged.6
Microbial growth medium
The high nutritive value of lipid emulsions promotes microbial growth 
after extrinsic contamination. Soon after the clinical introduction of 
propofol, cases of unexpected postoperative infections occurred.14−16 
Propofol 1%, without an antimicrobial agent added, support the 
growth of various bacteria and fungi, including Staphylococcus aureus, 
Escherichia coli, Pseudomonas aeruginosa, and Candida albicans.17−20 
For this reason, preservatives are commonly added to propofol. Only 
ethylenediaminetetraacetic acid (EDTA) and metabisulfate are 
currently approved by the Food and Drug administration.6 They have 
been successfully incorporated into propofol without deleteriously 
altering either the emulsion stability or its pharmacokinetic profile.6 
Despite the preservatives being effective enough to inhibit microbial 
Figure 1: The making of a lipid emulsion.
Note: Magnification: Lipid droplet portraying monolayer of phospholipid as 
emulsifier, which separates the interior lipid phase from the exterior aqueous 
phase. See text for discussion.
Table 3: Lipid emulsion preparations available for clinical use
Note: LCT: Long chain triglyceride; MCT: Medium chain triglyceride.
Name Fatty acid composition Emulsifier
Intralipid® 100% soybean oil Egg phospholipid
Lyposin II® 50% soybean oil; 50% safflower oil Egg phospholipid
Lyposin III® 100% soybean oil Egg phospholipid
Lipofunden MCT®Medialipide® 50% soybean oil; 50% coconut oil Egg phospholipid Sodium oleate
Structolipid® 64% soybean oil; 36% coconut oil Egg phospholipid
Omegaven® 100% fish oil Egg phospholipid
Lipoplus® 50% coconut; 40% soybean; 10% fish oil Egg phospholipid
ClinOleic® 80% olive oil; 20% soybean oil Egg phospholipid Sodium oleate
SMOFlipid® 30% coconut oil; 30% soybean oil; 25% olive oil; 15% fish oil Egg phospholipid Sodium oleate
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growth to levels similar to non-lipid formulation, strict asepsis is 
mandatory.6 This is specified as careful aseptic handling of propofol 
during preparation, single-patient use per ampoule, and the use of the 
ampoule within 6 h of breaking the seal.21
Propofol
In its pure form, propofol is a yellowish oil that freezes at only 19°C. 
2,6-di-isopropylphenol’s poor water miscibility is due to its highly 
lipophilic benzene ring and its single ionisable group. Indeed, the 
only suitable vehicles for propofol are lipophilic substances or 
organic solvents, the latter being toxic to humans.6 A miscellar 
emulsion of propofol and Cremophore EL underwent early, 
extensive human testing. This formulation was never marketed as 
it caused severe injection pain, a high incidence of anaphylaxis, 
and there were reports of associated peripheral neuropathy.6 Thus, 
despite its therapeutic potential as an anaesthetic having being 
discovered decades earlier, it was only in the 1980s that emulsion 
technology could produce a stable and physiologically compatible 
propofol preparation.6 Interestingly, propofol prepared as an 
emulsion exhibits greater potency, a smaller volume of distribution, 
less first-pass lung sequestration, and a decreased time to peak 
EEG effects when compared with equipotent doses of propofol in 
lipid-free formulations.6
Recent technological advances have resulted in the development 
of propofol nano-emulsions (Microfol™, NanoMedex 
Pharmaceuticals, Wisconsin, USA) with droplets less than 0.1 micron 
in diameter.22,23 Such nano-emulsions are colourless as droplets of 
this size do not reflect light. The decreased droplet size is associated 
with greater emulsion stability and less injection pain as there is less 
free aqueous phase propofol. Unlike current formulations, the 
propofol nano-emulsion is antimicrobial as the nanoparticles fuse 
with microbial membranes, causing pathogen lysis.22
Emulsified isoflurane
A promising development over the past fifteen years is isoflurane 
in a lipid emulsion.24 Animal studies have demonstrated rapid 
onset of general anaesthesia with intravenous, intraperitoneal, 
and even oral administration of emulsified isoflurane. A recent 
(unpublished) phase 1 clinical trial24 demonstrated a predictable 
onset of unconsciousness within 40 s after starting an intravenous 
infusion. Recovery after discontinuation of the intravenous 
infusion is via respiratory elimination of the isoflurane. In this 
respect, analysis of end-tidal isoflurane partial pressures would 
be a valid estimate of effect-site concentration of an intravenously 
administered agent. Emulsified isoflurane also has the potential 
to be utilised for regional anaesthesia as it has successfully been 
used in establishing epidural anaesthesia in rabbits,25 
subarachnoid anaesthesia in Beagle dogs,26 and intravenous 
regional anaesthetic in rat tails.27 There are additional benefits of 
emulsified isoflurane when employed in regional anaesthesia: it 
increases lignocaine’s convulsion threshold28 and when 
combined with lignocaine was synergistic in intravenous 
regional anaesthesia.27
Lipid emulsion for treatment of drug overdose
The discovery-hypothesis that lipid emulsion is an effective 
treatment for local anaesthetic systemic toxicity (LAST) 
originated in Guy Weinberg’s Chicago laboratory in 1998.29 The 
first successful human lipid emulsion resuscitation following 
LAST was reported in 2006.30 Subsequent case reports have 
described successful resuscitation of LAST from neonates to 
geriatrics, the oldest survivor being 92 years of age. These case 
reports have established the superiority of lipid resuscitation 
over vasopressor in LAST resuscitation,31 early administration 
thereof attenuating LAST progression.32 Successful lipid rescue 
has followed local anaesthesia toxicity involving bupivacaine,30,33 
ropivacaine,34,35 mepivacaine,35,36 and lignocaine.35,37 Although 
Intralipid® has been most commonly used,31 successful 
resuscitation from LAST has followed the use of other lipid 
emulsions such as SMOFlipid in pigs,38,39 Liposyn III following 
bupivacaine induced cardiac arrest,40 and Medialipid.41 Despite 
the 20% greater binding efficacy of long- compared with 
medium-chain triglycerides,42 Clinoleic® and Intralipid did not 
bind ropivacaine or bupivacaine differently.43 Therefore, the 
choice of lipid emulsion probably does not make a difference in 
the emergency situation — just use it! The management of LAST 
or other lipophilic drug toxicity is beyond the scope of this 
article. The reader is referred to http://www.asra.com, http://
Table 4: Advantages and disadvantages of lipid emulsions as carrier vehicle for specific drugs6,8
*See text for detailed discussion.
Advantages Disadvantages
1.  Reduction of injection pain, irritation and thrombophlebitis of diaze-
pam, etomidate and clarithromycin formulations 1. Emulsion instability
*
2.  Less nephrotoxicity and haemolysis associated with amphotericin B 
preparation
2.  Hyperlipidaemia: liposomes (droplets smaller than 0.08 micron) 
inhibit lipolysis and stimulate cholesterol synthesis
3.  Improved stability and solubility with the sodium phenobarbital, 
clarithromycin, all-trans-retinoic acid and physostigmine prepara-
tions due to decreased susceptibility to oxidation and hydrolysis 3.  Microbial growth medium
*
4.  Lipid emulsion formulations incorporating apo lipoprotein E in the 
phospholipid layer demonstrate a 70% increased hepatic uptake. 
This can provide targeted drug delivery in certain chemotherapeutic 
drugs
Table 5: Definition of terms defining lipid emulsion instability
Flocculation: Attractive forces overcome repulsive forces, resulting in droplet 
adherence
Coalescence: The thin film of surfactant between two flocculated droplets 
ruptures, resulting in mixing of the lipid phase; a larger, emulsified droplet is 
created
Creaming: As coalescence continues, droplet size increases and rises to the 
surface
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There is direct evidence that local anaesthetics, amiodarone and 
other lipid-soluble drugs are partitioned into the lipid phase:
•  Mazoit et al.’s in vitro study demonstrated that large amounts 
of local anaesthetic agents bind to lipid emulsion.42
•  Weinberg et al. analysed blood samples from one of their rat 
studies comparing vasopressin with Intralipid® resuscitation of 
LAST.47 Bupivacaine was present in far higher concentrations in 
the aqueous phase of the vasopressin than the lipid emulsion 
group.
•  Niiya et al. pre-treated pigs with lipid emulsion prior to 
inducing amiodarone ‘toxicity’.48 The lipid-treated group 
demonstrated less hypotension. Furthermore, after plasma 
ultracentrifugation, higher amiodarone levels were 
measured in the lipid phase.
•  Samuels et al. examined the validity of the lipid sink effect 
using an innovative model.49 They studied the effects of lipid 
emulsion therapy on four drugs, which each caused 
methaemoglobinaemia. Each drug was uniquely lipid soluble. 
The measurement of methaemoglobin concentrations 
represented an accurate, easy to measure endpoint. They 
hypothesised and clearly demonstrated that the more lipid 
soluble the drug, the more effective lipid emulsion therapy 
was in reducing methaemoglobin concentrations. Their 
conclusions strongly support the lipid sink theory.
•  French et al. studied 11 drugs associated with successful 
lipid emulsion resuscitation.50 After adding Intralipid® to 
serum, they investigated drug partitioning between serum 
and the lipid emulsion. The ability of lipid emulsions to 
extract drugs from the circulation was directly related to the 
drug’s lipophilicity.
Robust evidence also supports the ‘metabolic’ or ‘lipid flux’ effect. 
Stehr et al. demonstrated reversal of bupivacaine-induced 
cardiomyocyte dysfunction at lipid emulsion levels too low to 
sequester bupivacaine from the circulation.51 Further support for 
the metabolic theory is that following inhibition of 
cardiomyocytes’ ability to oxidise fatty acids, lipid emulsion 
therapy cannot reverse bupivacaine cardiotoxicity.52
Lipid emulsion as a therapy for ischaemia-
reperfusion injury attenuation
A potentially groundbreaking role of lipid emulsions is as an 
agent to attenuate ischaemia-reperfusion injury. During 
ischaemia, anaerobic cardiomyocyte metabolism results in 
lactate production, decreased intracellular pH, and intracellular 
calcium overload.53 Following reperfusion, electron transport 
chain reactivation produces reactive oxygen species that cause 
injury by three mechanisms:
(1)  attraction of neutrophils to injured cardiomyocytes;
(2)  aggravation of sarcoplasmic reticular dysfunction with 
further increases in cytosolic calcium; and
(3)  facilitating mitochondrial permeability transition pore 
opening.53
Opening of the mitochondrial permeability transition pore results 
in solute and free water influx, which ultimately leads to 
mitochondrial lysis. Upon rupturing, many pro-apoptotic factors 
usually isolated in the mitochondrial intermembranous space are 
released into the cardiomyocyte cytosol. This mechanism 
represents one of the main drivers of myocyte apoptosis (Figure 3). 
Lipid activates the reperfusion injury salvage kinase (RISK) 
pathway, which, in turn, activates the protein kinase B (Akt) and 
www.lipidrescue.org, and http://www.aagbi.org for up to date 
information and useful checklists.
The first successful lipid-facilitated resuscitation following 
overdose with non-local anaesthetic, lipophilic drugs (a 
combination of buproprion and lamotrigine) was reported two 
years after the first LAST ‘Lipid Rescue’.44 Subsequent case reports 
have endorsed lipid emulsion efficacy in treating overdoses of 
lipophilic drugs such as calcium channel blockers, β-blockers, 
psychotropics, tricyclic antidepressants, selective serotonin 
reuptake inhibitors, antiarrhythmic, and overdoses involving 
multiple, unknown drugs.35,45 It is important to appreciate that 
propofol contains insufficient lipid emulsion to be used as 
therapy in local anaesthetic or other lipophilic drug toxicity.
Weinberg’s group has hypothesised six mechanisms whereby 
lipid emulsion therapy is effective in LAST (Figure 2).31 Evidence is 
mounting in support of some of these proposed mechanisms 
with considerable backing for the ‘lipid sink’ and ‘lipid flux’ 
theories.
The ‘lipid sink’ or ‘partitioning’ effect presumably works by 
capturing lipophilic drugs in the lipid portion of the emulsion. 
There is both direct and indirect evidence for this mechanism. 
The indirect evidence includes:
•  Reversal of LAST-induced neurological symptoms has been 
achieved with lipid emulsion administration, despite the 
brain not readily utilising fatty acids for energy.31
•  Lipophilicity is the only discernible common characteristic 
explaining the variety of drug overdoses successfully 
resuscitated with lipid emulsions.31
•  Radiolabelled bupivacaine levels decline more rapidly in 
lipid-perfused rat hearts, compared with the lipid-free 
control groups.46
Figure 2: Proposed mechanisms of lipid resuscitation
Note: 1. Partitioning effect also termed the ‘lipid sink’ effect: capturing of local 
anaesthetic molecules inside the lipid droplet. 2. Metabolic effect, also termed the 
‘lipid flux’ effect: increased fatty uptake by mitochondria. 3. Membrane effect: direct 
interference of local anaesthetic binding to sodium channels by lipid emulsion. 
4. Cytoprotective effect: activation of Akt cascade leading to inhibition of GSK-3β. 
5. Promotion of calcium entry via voltage-dependent calcium channels, promoting 
myocardial excitation–contraction coupling. 6. Pharmacokinetic effect: accelerated 
hepatic ‘shunting’ of bupivacaine. Source: With permission: Wolter Kluwers Health 
Inc. From: Lipid emulsion infusion: resuscitation for local anesthetic and other drug 
overdose.31 Akt = a serine/threonine protein kinase important in cell survival, 
proliferation, and migration, also called protein kinase B; Ca2+ = calcium ion; Cn = 
carnitine; FA-Cn = fatty acyl carnitine; FFA = free fatty acids; GSK-3β = glycogen 
synthase kinase (phophorylates and thereby inhibits glycogen synthase; inhibition 
of GSK-3β has been implicated in preventing myocardial ischemia-reperfusion 
injury); LA = local anaesthetic; Na+= sodium ion.
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Adverse effects associated with lipid emulsion 
infusions
Most case reports describe successful resuscitation with less 
than the recommended upper limit of 10  ml/kg of a 20% 
Intralipid® preparation.64 This dose should be compared with the 
murine Intralipid® LD50 of 67.7  ±  10.7  ml/kg. Complications 
following lipid emulsion administered as part of long-term 
parenteral nutritional are well known (Table 6).5,12,65−73 
Complications and concerns following acute administration of 
‘Lipid rescue’ are starting to be investigated.74
The following should be taken into consideration:
a.  Pharmacokinetic alterations: Lipid-containing parenteral 
nutrition is well described to interfere with the 
pharmacokinetics of certain drugs.75 It is currently not known 
whether intravenous lipid emulsion can deleteriously alter 
the bioavailability of important lipophilic resuscitation 
drugs such as amiodarone, lignocaine, beta-
adrenoreceptor, and calcium channel blockers.
b.  Effects of lipid emulsions on anaesthesia: There is no 
knowledge on how lipid emulsions affect the depth of 
anaesthesia per se. Considering emulsified isoflurane and 
that propofol is dissolved in Intralipid®, this is an important 
but hitherto unaddressed question. The only available 
study reported that depth of anaesthesia increased in rats 
administered thiopentone and lipid emulsion concomitantly.76
c.  Lipid anaphylaxis could occur, especially in patients with 
nut or soybean sensitivity.71
d.  Interference with laboratory and blood gas analysis despite 
blood ultracentrifugation has been reported to occur for 
more than 12 h following Lipid Rescue. Haemoglobin and 
methaemoglobin results are increased, and electrolyte and 
base excess estimation are incorrect.64 Such problems have 
created serious dilemmas regarding patient management 
and prevented one patient from becoming a transplant 
candidate.74
e.  Pancreatitis has been reported following lipid rescue. This 
had a strong temporal association with hypertriglyceridaemia, 
resolution occurring along with normalisation of the lipid 
profile.74
extracellular signal-regulating kinase (ERK) cascades.54,55 Both 
pathways converge to phosphorylate glycogen synthase kinase 
3-β (GSK 3- β). Glycogen synthase kinase 3-β inhibits the opening of 
the mitochondrial permeability transition pore with less apoptosis 
(see Figure 3).
Rahman et al.’s recent, pioneering work demonstrated that lipid 
emulsion was protective of the myocardial following ischaemia-
reperfusion damage.54 The mechanisms elucidated by this study 
included:
(1)  Lipid-emulsion-initiated preconditioning as a 70% 
decrease in infarct size was observed if lipid emulsion 
was administered prior to reperfusion.
(2)  Lipid emulsion administered at reperfusion improved 
functional recovery and decreased infarct size.
(3)  Lipid emulsion appeared to initiate postconditioning as 
the cardioprotection was sustained for a time after 
terminating the infusion.
Similar results have been shown in two other publications.55,56 
Lipid emulsion treatment improved contractility following 
ischaemia reperfusion in isolated mouse cardiomyocytes.57 
Interestingly, emulsified isoflurane exhibits a potent, pre- and 
post-conditioning effect in animal ischaemia-reperfusion 
models of cardiomyocytes,58,59 kidney,60 brain,61 lung and liver62 
cells, future work in this field being eagerly awaited.
Although promising, many questions need answering before 
lipid emulsion therapy is hailed as the new ‘magic bullet’ in 
cardioprotection.63 For example, the exact chemical compound 
responsible for these protective effects is not yet known. 
Furthermore, all work until now has been performed in rats, ex 
vivo Langendorff mouse heart models, or isolated muscle 
preparations. Therefore, a question that needs addressing is 
whether these in vitro experiments can be reproduced in animals, 
and eventually in humans.
Figure 3: Ischaemia-reperfusion injury and lipid emulsion
Note: This diagram depicts the central role of the mitochondrial permeability 
transition pore (mPTP) in ischaemia-reperfusion injury and demonstrates the 
pathway whereby lipid emulsions attenuate it. ROS = reactive oxygen species; Ca2+ 
= intracytosolic calcium concentration; mPTP = mitochondrial permeability 
transition pore; GSK 3-β - ℗ = Phosphorylated glycogen synthase kinase 3-β; Akt 
cascade = protein kinase B cascade; ERK cascade = extracellular signal-regulating 
kinase cascade; RISK = reperfusion injury salvage kinase.
Table 6: Adverse effects associated with the long-term administration of 
lipid emulsions5,12,65−73
1. Dyslipidaemia (hypercholesterolaemia and hypertriglyceridaemia) 
2. Modulation of cell-mediated immunity
3. Increased inflammation 
4. Increased oxidative stress 
5. Fat emboli (pulmonary, splenic, placental, cerebral)
6. Reticulo-endothelial dysfunction
7. Thrombophlebitis with peripheral administration
8. Interference with laboratory results
9. Increased oxygen consumption
10. Increased shunt fraction and pulmonary artery pressure in ARDS
11. Anaphylaxis
12. Pancreatitis
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Conclusion
The therapeutic roles of lipid emulsion have expanded far beyond the 
realms of nutrition. Many lipophilic drug solutions are formulated as 
lipid emulsions, including propofol. A serious and underappreciated 
disadvantage of these preparations is that of emulsion instability, 
which occurs when the preparations are diluted with charged 
solutions. Anaesthetists’ future armamentarium may include 
emulsified isoflurane. Lipid emulsions have a well-established role in 
the management of local anaesthetic toxicity, as well as acting as an 
antidote in various other lipophilic drug overdoses. The evidence 
supporting the ‘lipid sink’ and the ‘lipid flux’ theories is growing in 
strength. Lipid emulsion therapy, both alone and in combination with 
isoflurane, has promising cytoprotective effects following ischaemia 
reperfusion in animals. Reported complications in patients receiving 
lipid rescue include pancreatitis, interference with laboratory results, 
and pharmacokinetic alteration of drugs used during lipid 
resuscitation.
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Note







where V is the rate of diffusion, A is the surface area available for diffusion, 
D is the diffusion coefficient, Solubility/√Molecular mass, P1−P2 is the 
partial pressure difference governing diffusion, t is the thickness of the 
membrane or diffusion distance.
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